SNDX · Syndax Pharmaceuticals Inc

$19.54 -0.62 (-3.08%) At close · Aug 28

Russell 2000 member Rebalance outlook locked

Market Cap

$1.74B

89.30M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael A. Metzger	Chief Executive Officer	$754,300	—	$2,021,965	$3,454,360	$848,588	$10,000	$7,089,213
Nick Botwood	M.B.B.S. Head of Research & Development, Chief Medical Officer	$345,682	—	$285,792	$1,913,500	$334,125	—	$2,879,099
Keith Goldan	Chief Financial Officer	$516,900	—	$569,609	$1,048,645	$325,648	$10,000	$2,470,802
Luke J. Albrecht	General Counsel and Secretary	$496,900	—	$540,309	$949,000	$335,408	$10,000	$2,331,617
Steve Closter	Chief Commercial Officer	$485,300	—	$496,359	$806,650	$327,578	$10,000	$2,125,887

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael A. Metzger	Chief Executive Officer	$715,000	—	$3,258,450	$3,208,211	$515,515	$10,000	$7,707,176
Steve Closter	Chief Commercial Officer	$364,167	—	$745,280	$2,222,927	$214,763	$10,000	$3,557,137
Neil Gallagher	M.D., Ph.D. President, Head of Research & Development	$546,000	—	$1,065,274	$1,037,205	$269,588	$10,000	$2,928,067
Keith Goldan	Chief Financial Officer	$497,000	—	$1,040,476	$1,047,416	$229,241	$10,000	$2,824,133
Luke J. Albrecht	General Counsel and Secretary	$471,000	—	$868,920	$897,280	$222,548	$10,000	$2,469,748

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael A. Metzger	Chief Executive Officer	$678,400	—	—	$8,023,803	$417,216	$8,000	$9,127,419
Neil Gallagher	M.D., Ph.D. President, Head of Research & Development	$386,458	—	—	$3,318,187	$182,229	$5,300	$3,892,174
Keith Goldan	Chief Financial Officer	$470,300	—	—	$2,151,384	$196,350	$8,000	$2,826,034
Luke J. Albrecht	General Counsel and Secretary	$442,099	—	—	$1,957,815	$181,261	$8,000	$2,589,175

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael A. Metzger	Chief Executive Officer	$640,000	—	—	$3,062,276	$403,200	$8,000	$4,113,476
Steve M. Sabus	Chief Commercial Officer	$37,950	—	—	$3,878,100	—	—	$3,916,050
Keith Goldan	Chief Financial Officer	$249,900	—	$49,998	$2,497,890	$186,750	$8,000	$2,992,538
Catherine Madigan	Chief Medical Officer	$503,540	—	—	$1,980,213	$152,161	$8,000	$2,643,914
Briggs Morrison	President, Head of Research and Development and Former Chief Executive Officer	$637,500	—	—	$1,393,983	$334,688	$8,000	$2,374,171
Luke J. Albrecht	General Counsel and Secretary	$421,000	—	—	$862,253	$176,820	$8,000	$1,468,073
Alexander Nolte	Vice President, Chief Accounting Officer and Former Interim Principal Financial Officer	$338,000	—	—	$323,364	$91,500	$8,000	$760,864

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Briggs Morrison	President, Head of Research and Development and Former Chief Executive Officer	$618,563	—	—	$2,968,473	$309,280	$8,000	$3,904,316
Michael A. Metzger	Chief Executive Officer	$594,104	—	—	$2,434,751	$297,050	$8,000	$3,333,905

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Briggs Morrison	President, Head of Research and Development and Former Chief Executive Officer	$600,547	—	—	$1,273,590	$285,260	$6,000	$2,165,397
Michael A. Metzger	Chief Executive Officer	$576,800	—	$142,050	$950,701	$273,980	$6,000	$1,949,531

Executive changes

Person	Role	Change	Effective	Filed
Michael A. Metzger	director	Appointed	2026-06-10	2026-06-10
Pierre Legault	director	Appointed	2026-06-10	2026-06-10
William Meury	member of the Board of Directors	Resigned	2025-06-24	2025-06-26
Neil Gallagher	President, Head of Research and Development	Resigned	—	2025-05-16
Catherine Madigan, M.D.	Chief Medical Officer	Terminated	2024-12-20	2024-12-20
Briggs W. Morrison, M.D.	Class III member of our Board	Resigned	2024-05-14	2024-05-15
Aleksandra Rizo, M.D., Ph.D.	Class III member of the Board	Appointed	2024-05-15	2024-05-15
Steven Closter	Chief Commercial Officer	Appointed	2024-03-18	2024-03-18
Alexander Nolte	Vice President, Chief Accounting Officer and Principal Accounting Officer	Resigned	2023-05-05	2023-05-08
Neil Gallagher	President, Head of Research and Development	Appointed	2023-04-10	2023-03-30
Neil Gallagher, M.D., Ph.D.	President, Head of Research and Development	Appointed	2023-04-10	2023-03-30
Steve Sabus	Chief Commercial Officer	Appointed	2022-12-05	2022-12-05
Sharon Klahre	Vice President, Investor Relations and Communications	Appointed	—	2022-06-13
Keith A. Goldan	principal financial officer and treasurer	Appointed	—	2022-06-13
Keith A. Goldan	Chief Financial Officer	Appointed	2022-06-13	2022-06-13
Michael L. Meyers, M.D., Ph.D.	Chief Medical Officer	Retired	2022-03-01	2022-03-01
Kate Madigan, M.D.	Chief Medical Officer	Appointed	2022-03-01	2022-03-01
Fabrice Egros	Board of Directors	Resigned	2022-02-23	2022-02-24
Briggs W. Morrison, M.D.	President, Head of Research and Development (R&D)	Appointed	2022-02-03	2022-02-03
Michael A. Metzger	Chief Executive Officer	Appointed	2022-02-03	2022-02-03
Briggs W. Morrison, M.D.	President, Head of Research and Development	Appointed	2022-02-02	2022-02-03
Michael A. Metzger	Chief Executive Officer	Appointed	2022-02-02	2022-02-03
Alexander Nolte	interim principal financial officer	Appointed	2021-10-22	2021-10-04
Alexander Nolte	principal accounting officer	Appointed	2021-10-22	2021-10-04
Daphne Karydas	chief financial officer, treasurer, principal financial officer and principal accounting officer	Resigned	2021-10-22	2021-10-04

Key facts CIK 1395937 CUSIP 87164F105 13F (30d) 217 filings 214 filers Visit website Investor relations